Talquetamab in multiple myeloma
Initial results of the phase I trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple myeloma in the fourth line or later setting. It demonstrated a similar efficacy profile and durability of respo...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2023-10-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11313 |